ADCs in the Treatment of Breast Cancer and Gastric Cancer and Managing AEs Associated with ADCs : Episode 1

Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

August 18, 2022

By Sarah Donahue, MPH, NP, AOCNP
Jamie Carroll, APRN, CNP, MSN

Video

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

Now Viewing

EP: 1.Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

EP: 2.Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers

EP: 3.Management of Interstitial Lung Disease Related to T-DXd in Breast or Gastric Cancers

EP: 4.Selecting Appropriate Patients with MBC for T-DXd and Counseling for AEs

EP: 5.Sequencing Therapy in MBC in Second Line and Beyond

EP: 6.Patient Profile 2: A Patient With HER2+ MBC Treated With T-DM1 who Develops Neuropathy

EP: 7.Role of T-DM1 in Patients With HER2+ Breast and Gastric Cancers

EP: 8.Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

EP: 9.A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer

EP: 10.Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

EP: 11.First- and Second-Line Treatment Options for HER2+ Gastric Cancer

EP: 12.T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs

EP: 13.Ongoing Clinical Trials With T-DXd in HER2+ Gastric Cancer

EP: 14.Patient Profile 4: A Patient with HER2+ Gastric Cancer Treated With T-DXd Who Develops Diarrhea

EP: 15.T-DXd in HER2+ Gastric Cancer: Educating Patients About Risk of Diarrhea

EP: 16.Role of the Broader Healthcare Team in Managing AEs Associated With T-DXd

EP: 17.Novel Clinical Trials With ADCs in Gastric Cancer

EP: 18.Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care

Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC

Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

Safety Management With Amivantamab Plus Lazertinib in NSCLC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777